In China, chronic respiratory diseases (CRD) are characterized by high prevalence, disability rate, and mortality rate, imposing a severe disease burden. Home non-invasive ventilation (HNIV) therapy can improve ventilation, alleviate respiratory muscle fatigue, enhance oxygenation and carbon dioxide retention, delay the progression of various CRD, and even improve survival. However, there is currently a lack of long-term management standards and standardized guidance for patients receiving HNIV therapy in China. The Respiratory Therapy Group of the Chinese thoracic Society and Chinese Association of Rehabilitation Medicine, has summarized 11 questions related to HNIV for different diseases, answered various questions, and put forward modification suggestions. This consensus aims to provide references for frontline clinical staff, promote the standardization of HNIV application in China, and improve the level of treatment.Summary of recommendationsQuestion 1. For which patients is HNIV suitable?Recommendation: HNIV is recommended for patients with ventilatory dysfunction due to various causes, such as: obstructive sleep apnea syndrome [high-quality evidence, strong recommendation], chronic obstructive pulmonary disease [high/moderate-quality evidence, strong recommendation], obesity hypoventilation syndrome [moderate/low-quality evidence, strong recommendation], and neuromuscular diseases [low-quality evidence, strong recommendation].Question 2. When should HNIV be initiated?Recommendation: The timing for initiating HNIV therapy should be based on a comprehensive assessment of disease diagnosis, severity, symptoms, and comorbidities. Early standardized intervention is a crucial measure for improving prognosis and reducing long-term disease burden. Specific recommended indications are listed in Table 2. [high/moderate quality evidence, strong recommendation]Question 3. How should health education on HNIV be conducted?Recommendation: All HNIV patients should receive educational training. The five-step training method is recommended as the preferred approach for educating HNIV patients and their families. [Moderate-quality evidence, weak recommendation]Question 4. How to properly select a home non-invasive ventilator?Recommendations: When selecting a home non-invasive ventilator, patients should first consult a professional physician or respiratory therapist to obtain specialized advice based on their specific condition. Physicians should make decisions by comprehensively considering the patient’s disease type and severity, ventilator modes and parameters, synchrony, comfort, remote monitoring requirements, and financial circumstances. Refer to Table 3 for ventilation mode selection based on different diseases.Question 5. How should accessories for HNIV be selected?Recommendation: Mask selection should be based on disease type, dynamic assessment of the patient’s breathing pattern, and patient preference, with regular reassessment of fit during follow-up [High/moderate-quality evidence, strong recommendation]. Active heated humidifiers are recommended as the first choice for HNIV patients [Low-quality evidence, weak recommendation].Question 6. How should HNIV parameters be set and adjusted?Recommendation: Parameter adjustments should be performed in hospital and community settings. Long-term home use should only commence after confirming appropriate and safe settings. Avoid patients or caregivers making arbitrary adjustments that may cause adverse events. [Moderate-quality evidence, strong recommendation]Pressure settings for NIV should be tailored to the patient’s underlying disease and clinical objectives. Additional parameters including backup rate, inspiratory sensitivity, pressure rise time, and expiratory sensitivity must also be configured. The setup process is summarized in Figure 1. [Moderate-quality evidence, strong recommendation]Question 7. What is the recommended daily usage duration for HNIV?Recommendation: For patients using HNIV due to sleep apnea or sleep-related hypoventilation, it is recommended to use the device for at least 4 hours daily on more than 70% of nights, with usage duration covering sleep periods as much as possible. For patients using HNIV due to chronic hypercapnia, daily use of at least 5 - 6 hours is required, with priority given to nighttime use. [Low-quality evidence, weak recommendation]Question 8. When should respiratory support be adjusted during HNIV?Recommendation: Assess the efficacy of HNIV based on clinical and physiological criteria to determine whether to continue ventilatory support [Moderate-quality evidence, strong recommendation]. If disease progression or complications arise, and HNIV can no longer maintain effective ventilation, discontinue HNIV and seek hospital care promptly [Low-quality evidence, strong recommendation]. HNIV should not be discontinued in patients requiring intermittent or continuous HNIV during exercise [Moderate-quality evidence, strong recommendation].Question 9. How should complications associated with HNIV be managed?Recommendation: Common complications of noninvasive ventilation include skin pressure injury, air leak, patient-ventilator asynchrony, and thick sputum. These should be actively prevented and managed during HNIV. [Moderate-quality evidence, strong recommendation]Question 10. How should the effectiveness of HNIV be assessed and followed up?Recommendation: Close monitoring and follow-up are recommended for patients receiving home noninvasive ventilation. Monitoring indicators and follow-up frequency are summarized in Table 6. [Moderate-quality evidence, GPS]Question 11. How should the management pathway for HNIV be established and optimized?Recommendations: Establish a tiered, dynamic, and individualized HNIV management pathway based on patient condition characteristics, technical support availability, and home care capabilities: ① For high-risk acute exacerbation/unstable patients: Primarily use the traditional "hospital-community-home" model supplemented by self-management; for low-risk acute exacerbation/stable patients: Primarily use self-management with IoT-based remote monitoring where feasible. ② Dynamically adjust based on disease stage: intensify in-person training during the initial phase and gradually transition to remote monitoring during the stable phase; ③ Promote multidisciplinary collaboration, utilize smart devices for real-time monitoring, and ensure data security; ④ Enhance patient self-management capabilities through standardized education and regular follow-ups. [Low-quality evidence, GPS]
Objective To investigate the alternatives of different endoscopic drainages for acute cholangitis of severe type (ACST) in elderly patients with chronic respiratory disease. Methods The clinical data of 74 cases of ACST in elderly patients with chronic respiratory disease undergoing 3 kinds of drainages, endoscopic retrograde double biliary stent drainage (D-ERBD), endoscopic retrograde single biliary stent drainage (S-ERBD), or endoscopic nasobiliary drainage (ENBD) in the First Hospital of Lanzhou University from October 2005 to October 2015 were collected to analyze prospectively. Results Compared with preoperative, the white blood cell (WBC), direct bilirubin (DBIL), temperature, and abdominal pain NRS evaluation in 48 h after operation in 3 groups all decreased, the difference was statistically significant (P＜0.05). Compared among 3 groups, there were no significant difference among the incidences of postoperative hyperamylasemia, pancreatitis and gastrointestinal hemorrhage (P＞0.05). The group of ENBD was more likely to develop pulmonary infection and achieve a secondary treatment than other 2 groups (P＜0.05). Totally 5 patients died in 3 groups, with a mortality of 6.76%, but the mortality rates were similar among the 3 groups (P＞0.05). The deaths were predominantly caused by multiple organ failure (MOF), 4 cases of which were caused by respiratory failure related to respiratory infection. Conclusion The alternative of endoscopic retrograde double biliary stent drainage (D-ERBD) can not only alleviate cholangitis rapidly, but it can reduce the incidence of aspiration pneumonia.